Search

Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.

Dear Editor, BRAF-V600E-targeted-therapy (TT) and immune-checkpoint-inhibitors (ICIs) have revolutionized the treatment of metastatic melanoma (MM). Subcutaneous and bone lesions in patients with MM under TT should not be immediately interpreted as disseminated metastasis, as they could also represent drug-induced TT effects. PET-CT-scan showed a partial lymph-node response, contrasting with the occurrence of hypermetabolic subcutaneous lesions and bone foci of the tibias/calcaneus/right radius and humerus (Figure 1e). [Extracted from the article]